'Primary end point' presentation slideshows

Neuronal Nicotinic Receptors

Neuronal Nicotinic Receptors. In Depth Analysis of Breaking Research, Drug Development News & Pipeline Activity. Next Edition: January 13 th 2008. UpdatesPlus: Subscription Information.

996 views • 62 slides

Oral Treatments in Development for MS

1.45k views • 56 slides

Welcome Ask The Experts March 24-27, 2007 New Orleans, LA

Welcome Ask The Experts March 24-27, 2007 New Orleans, LA. Dr. Germano Di Sciascio. ARMYDA-ACS: Atorvastatin Pretreatment Improves Outcome in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention.

585 views • 42 slides

Novel Biologics in the Treatment of Colorectal Cancer

Novel Biologics in the Treatment of Colorectal Cancer. Howard S. Hochster, MD Professor of Medicine, NYU School of Medicine Director, GI Program NYU Cancer Institute. Current Therapies. Fluoropyrimidines Oxaliplatin Irinotecan Bevacizumab; anti-angiogenic MoAB

799 views • 37 slides

Hypertension-so what has changed? Review of ASCOT and NICE Guidelines

Hypertension-so what has changed? Review of ASCOT and NICE Guidelines. Cardiovascular Study day Cheltenham Racecourse 10 th October 2006 Dr Jim Moore. ASCOT- BPLA: Rationale.

469 views • 32 slides

March 19, 2002 Overview of Colorectal Chemoprevention Trials Bernard Levin, M.D. The University of Texas M. D. Anderson

March 19, 2002 Overview of Colorectal Chemoprevention Trials Bernard Levin, M.D. The University of Texas M. D. Anderson Cancer Center. 5-20 yrs. 5-15 yrs. ADENOMA. Normal. Mild. Moderate. Severe. Cancer. K-ras. SMAD 2 SMAD 4 DCC. p53. APC , bcl -2, c- myc Hypomethylation COX-2.

312 views • 30 slides

Background

Effect of Early revascularization versus delayed revascularization versus medical therapy on inpatient mortality in patients with non ST elevation MI in a community hospital Setting Owais Jeelani ,MBBS

389 views • 30 slides

Bioequivalence of Locally Acting Gastrointestinal Acting Drugs: Scientific Considerations

Bioequivalence of Locally Acting Gastrointestinal Acting Drugs: Scientific Considerations . James E. Polli University of Maryland July 23, 2008. Low Solubility Immediate Release Dosage Forms of Locally-acting GI Drugs.

681 views • 30 slides

Canadian Cardiovascular Society Antiplatelet Guidelines

Canadian Cardiovascular Society Antiplatelet Guidelines. ANTIPLATELET THERAPY IN PATIENTS WITH CHRONIC KIDNEY DISEASE. Working Group: Neesh Pannu , MD, SM, FRCP; Alan D. Bell, MD, CCFP. Objectives.

560 views • 29 slides

Evaluation of a novel, rationally designed, low-molecular-weight heparin during elective PCI: Results of the Phase 2 EM

Evaluation of a novel, rationally designed, low-molecular-weight heparin during elective PCI: Results of the Phase 2 EMINENCE Trial. Sunil V. Rao MD for the EMINENCE Investigators. EMINENCE Trial: Disclosures. Presenter disclosures

505 views • 28 slides

Ethical issues in clinical trials

Ethical issues in clinical trials. Bernard Lo, M.D. February 16, 2012. Conflicts of interest. None. Issues to discuss. Use of placebo control where an effective treatment exists Informed consent Participants who develop adverse outcomes. Osteoporosis RCTs.

398 views • 28 slides

Multiple Small Feedings of the Mind WV ACP Chapter Meeting 2008

417 views • 27 slides

M. Seyfarth, A. Kastrati, J. Mehilli, F.-J. Neumann, J. ten Berg, O. Bruskina, F. Dotzer, J. Pache, J. Dirschinger, P.

One-year Clinical Outcomes in the ISAR-REACT 2 Trial, a Randomized Comparison of Abciximab Versus Placebo in Patients With non-ST Segment Elevation Acute Coronary Syndromes Undergoing PCI After Pretreatment With Clopidogrel.

335 views • 19 slides

ARMYDA-5 ( A ntiplatelet therapy for R eduction of MY ocardial D amage during A ngioplasty) study

330 views • 18 slides

S TI571 P rospective I nternational R andom I sed T rial

S TI571 P rospective I nternational R andom I sed T rial

361 views • 16 slides

LONG-TERM OUTCOME OF DRUG-ELUTING STENTS COMPARED WITH BARE METAL STENTS IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION

LONG-TERM OUTCOME OF DRUG-ELUTING STENTS COMPARED WITH BARE METAL STENTS IN ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION Results of the Paclitaxel- or Sirolimus-Eluting Stent Versus Bare Metal Stent in Primary Angioplasty (PASEO) Randomized Trial.

312 views • 12 slides

Standard Medical Therapy

211 views • 9 slides

Lipid and Lipoprotein Parameters at Baseline and Drug Treatment: METEOR Trial

Lipid and Lipoprotein Parameters at Baseline and Drug Treatment: METEOR Trial.

303 views • 4 slides

DIABETES trial

DIABETES trial. 149 patients with type 2 diabetes (1/3 on insulin) and native coronary lesions appropriate for stent implantation . Cypher sirolimus-eluting stent. Bare-metal stent. Primary Endpoint: In-stent and late lumen loss at 9 months (determined by QCA) Secondary Endpoints:

186 views • 4 slides

Valsartan shows no difference in the composite PEP ( cardiovascular event ) vs amlodipine and mitigate results o

Valsartan shows no difference in the composite PEP ( cardiovascular event ) vs amlodipine and mitigate results on MI and death. Matsushita K et al. The NAGOYA-Heart trial. Late-breaking clinical trial. ACC Annual Scientific session 2011. SUMMARY.

188 views • 4 slides